$NBP News

NovaBridge Biosciences Appoints Mark Hagler As President And Chief Commercial Officer

NovaBridge's Givastomig Could Drive A Major Re-Rating

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration - Slideshow

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

NovaBridge Biosciences Secures FDA Alignment For Accelerated Approval Pathway For Givastomig In 1L HER2-, CLDN18.2+, PD-L1+ GEC Patients

NovaBridge Biosciences Secures FDA Alignment For Accelerated Approval Pathway For Givastomig In 1L HER2-, CLDN18.2+, PD-L1+ GEC Patients

NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease

NovaBridge Biosciences shares are trading lower. The company announced topline results from the Phase 2a study of VIS-101, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases.

Novabridge Biosciences' Topline Results From The Phase 2A Study Of VIS-101 For Retinal Vascular Diseases Show That VIS-101 Produced Rapid, Robust, And Durable Treatment Responses

NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

NovaBridge Appoints Emmett T. Cunningham Jr. As Vice Chairman Of The Board To Accelerate Global Biotech Platform And Drive Shareholder Value

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

NovaBridge Biosciences Doses First Participant In Phase 2 Combination Trial Of Givastomig With Nivolumab And Chemotherapy In Patients With HER2-Negative, 1L Metastatic Gastric Cancer

NovaBridge Biosciences shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $7 to $9.